Vebreltinib

Vebreltinib
Clinical data
Other names	Bozitinib; APL-101; PBL-1001
Routes of; administration	Oral
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name 6-(1-Cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine;
CAS Number	1440964-89-5;
PubChem CID	72202701;
DrugBank	DB16823;
ChemSpider	72388443;
UNII	2WZP8A9VFN;
ChEMBL	ChEMBL4650443;
Chemical and physical data
Formula	C20H15F3N8
Molar mass	424.391 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F;
	InChI InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3; Key:QHXLXUIZUCJRKV-UHFFFAOYSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer.^[1]^[2]

Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways.^[3]

In China, it is approved for the treatment of non-small-cell lung cancer (NSCLC) with MET exon 14 skipping mutations.^[4]

References

^ Hong L, Zhang J, Heymach JV, Le X (2021). "Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer". Therapeutic Advances in Medical Oncology. 13: 1758835921992976. doi:10.1177/1758835921992976. PMC 7890719. PMID 33643443.
^ Han Y, Yu Y, Miao D, Zhou M, Zhao J, Shao Z, et al. (February 2024). "Targeting MET in NSCLC: An Ever-Expanding Territory". JTO Clinical and Research Reports. 5 (2): 100630. doi:10.1016/j.jtocrr.2023.100630. PMC 10867448. PMID 38361739.
^ "Vebreltinib". NCI Drug Dictionary. U.S. National Institutes of Health.
^ "Vebreltinib Receives Approval in China For MET Exon 14+ NSCLC". onclive.com. November 16, 2023.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] Hong L, Zhang J, Heymach JV, Le X (2021). "Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer". Therapeutic Advances in Medical Oncology. 13: 1758835921992976. doi:10.1177/1758835921992976. PMC 7890719. PMID 33643443.

[2] Han Y, Yu Y, Miao D, Zhou M, Zhao J, Shao Z, et al. (February 2024). "Targeting MET in NSCLC: An Ever-Expanding Territory". JTO Clinical and Research Reports. 5 (2): 100630. doi:10.1016/j.jtocrr.2023.100630. PMC 10867448. PMID 38361739.

[3] "Vebreltinib". NCI Drug Dictionary. U.S. National Institutes of Health.

[4] "Vebreltinib Receives Approval in China For MET Exon 14+ NSCLC". onclive.com. November 16, 2023.

[1]

[2]

[3]

[4]